- Home
- DMO vs LPTX Comparison
DMO vs LPTX Comparison
Compare DMO & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMO
- LPTX
- Stock Information
- Founded
- DMO 2009
- LPTX 2011
- Country
- DMO United States
- LPTX United States
- Employees
- DMO N/A
- LPTX N/A
- Industry
- DMO Trusts Except Educational Religious and Charitable
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DMO Finance
- LPTX Health Care
- Exchange
- DMO Nasdaq
- LPTX Nasdaq
- Market Cap
- DMO 136.1M
- LPTX 111.0M
- IPO Year
- DMO N/A
- LPTX N/A
- Fundamental
- Price
- DMO $12.05
- LPTX $3.05
- Analyst Decision
- DMO
- LPTX Strong Buy
- Analyst Count
- DMO 0
- LPTX 5
- Target Price
- DMO N/A
- LPTX $10.40
- AVG Volume (30 Days)
- DMO 49.6K
- LPTX 88.3K
- Earning Date
- DMO 01-01-0001
- LPTX 11-11-2024
- Dividend Yield
- DMO 12.06%
- LPTX N/A
- EPS Growth
- DMO N/A
- LPTX N/A
- EPS
- DMO N/A
- LPTX N/A
- Revenue
- DMO N/A
- LPTX N/A
- Revenue This Year
- DMO N/A
- LPTX N/A
- Revenue Next Year
- DMO N/A
- LPTX N/A
- P/E Ratio
- DMO N/A
- LPTX N/A
- Revenue Growth
- DMO N/A
- LPTX N/A
- 52 Week Low
- DMO $10.00
- LPTX $1.24
- 52 Week High
- DMO $11.80
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- DMO 52.57
- LPTX 63.89
- Support Level
- DMO $11.90
- LPTX $2.71
- Resistance Level
- DMO $12.14
- LPTX $2.88
- Average True Range (ATR)
- DMO 0.11
- LPTX 0.16
- MACD
- DMO 0.01
- LPTX -0.02
- Stochastic Oscillator
- DMO 57.58
- LPTX 90.15
About DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .